Research efforts to develop a living-cell based approach to the treatment of type 1 diabetes have been galvanized by a global strategic collaboration between diabetes heavyweight Eli Lilly & Co. and US biotech Sigilon Therapeutics that includes a large upfront of $63m for the small start-up, and milestone payments.
News of the Lilly/Sigilon collaboration, released on Apr. 4, comes just months after another US biotech active in the living...